Candel Therapeutics与RTW签署1亿美元特许权融资协议，助力前列腺癌疗法Aglatimagene Besadenovec（CAN-2409）商业化布局

美股速递02-20

Candel Therapeutics（纳斯达克代码：CADL）近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec（研发代号CAN-2409）在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入提供关键资金支持。

CAN-2409作为一种基于腺病毒载体的免疫激活疗法，已在前列腺癌的临床研究中展现出激活患者自身免疫系统对抗肿瘤的潜力。此次融资协议的落地，标志着该疗法向商业化阶段迈出关键一步，也为晚期前列腺癌患者提供了新的治疗希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1125258398?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-20 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125258398","market":"us","top_or_hot":-1,"title":"Candel Therapeutics与RTW签署1亿美元特许权融资协议，助力前列腺癌疗法Aglatimagene Besadenovec（CAN-2409）商业化布局","media":"美股速递","content":"<p>Candel Therapeutics（纳斯达克代码：CADL）近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec（研发代号CAN-2409）在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入提供关键资金支持。</p>\n<p>CAN-2409作为一种基于腺病毒载体的免疫激活疗法，已在前列腺癌的临床研究中展现出激活患者自身免疫系统对抗肿瘤的潜力。此次融资协议的落地，标志着该疗法向商业化阶段迈出关键一步，也为晚期前列腺癌患者提供了新的治疗希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics与RTW签署1亿美元特许权融资协议，助力前列腺癌疗法Aglatimagene Besadenovec（CAN-2409）商业化布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics与RTW签署1亿美元特许权融资协议，助力前列腺癌疗法Aglatimagene Besadenovec（CAN-2409）商业化布局\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-20 05:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Candel Therapeutics（纳斯达克代码：CADL）近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec（研发代号CAN-2409）在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CADL","symbol_name":"Candel Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1125258398","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125258398","pubTimestamp":1771534955,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Candel Therapeutics近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入提供关键资金支持。此次融资协议的落地，标志着该疗法向商业化阶段迈出关键一步，也为晚期前列腺癌患者提供了新的治疗希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CADL":"Candel Therapeutics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Candel Therapeutics and RTW signed a US $100 million concession financing agreement to help commercialize the prostate cancer therapy Aglatimagene Besadenovec (CAN-2409)","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":1},"content_text":"Candel Therapeutics（纳斯达克代码：CADL）近日宣布与生物医药投资机构RTW达成一项规模达1亿美元的特许权融资协议。该资金将专项用于支持其核心候选药物Aglatigmatene Besadenovec（研发代号CAN-2409）在局限性前列腺癌领域的潜在商业化推进。此次合作通过未来药物销售的特许权收益作为融资对价，在降低股权稀释风险的同时，为CAN-2409的临床开发及市场准入提供关键资金支持。\nCAN-2409作为一种基于腺病毒载体的免疫激活疗法，已在前列腺癌的临床研究中展现出激活患者自身免疫系统对抗肿瘤的潜力。此次融资协议的落地，标志着该疗法向商业化阶段迈出关键一步，也为晚期前列腺癌患者提供了新的治疗希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125258398","isCrawlerRequest":true}